Status:
COMPLETED
World Maternal Antifibrinolytic Trial_2
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
Wellcome Trust
Bill and Melinda Gates Foundation
Conditions:
Intrapartum - Moderate and Severe Anaemia
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexam...
Detailed Description
Anaemia is a cause and consequence of PPH. A cohort study in Assam, India found that women with moderate or severe anaemia had a greatly increased risk of PPH. Women with moderate anaemia had a 50% in...
Eligibility Criteria
Inclusion
- Women with moderate or severe anaemia (haemoglobin level \<100 g/L or packed cell volume \<30%) after giving birth vaginally where the responsible clinician is substantially uncertain whether to use TXA
Exclusion
- Women who are not legally adult (\<18 years) and not accompanied by a guardian
- Women with a known allergy to tranexamic acid or its excipients
- Women who experience postpartum haemorrhage before the umbilical cord is cut or clamped.
Key Trial Info
Start Date :
August 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2023
Estimated Enrollment :
15068 Patients enrolled
Trial Details
Trial ID
NCT03475342
Start Date
August 24 2019
End Date
October 29 2023
Last Update
January 10 2024
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Mother & Child Hospital
Akure, Nigeria
2
University of Medical Sciences Teaching Hospital
Akure, Nigeria
3
Adeoyo Maternity Hospital
Ibadan, Nigeria
4
Ilorin General Hospital
Ilorin, Nigeria